Impact of nutritional supplementation during pregnancy on antibody responses to diphtheria-tetanus-pertussis vaccination in infants: A randomised trial in The Gambia.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
08 2019
Historique:
received: 25 01 2019
accepted: 27 06 2019
entrez: 7 8 2019
pubmed: 7 8 2019
medline: 10 1 2020
Statut: epublish

Résumé

Exposure to a nutritionally deficient environment during fetal life and early infancy may adversely alter the ontogeny of the immune system and affect an infant's ability to mount an optimal immune response to vaccination. We examined the effects of maternal nutritional supplementation during pregnancy on infants' antibody responses to the diphtheria-tetanus-pertussis (DTP) vaccine included in the Expanded Programme on Immunisation (EPI). The Early Nutrition and Immune Development (ENID) trial was a randomised, partially blinded trial conducted between April 2010 and February 2015 in the rural West Kiang region of The Gambia, a resource-poor region affected by chronic undernutrition. Pregnant women (<20 weeks' gestation) with a singleton pregnancy (n = 875) were randomised to receive one of four supplements: iron-folic acid (FeFol; standard of care), multiple micronutrient (MMN), protein-energy (PE), or PE + MMN daily from enrolment (mean [SD] 13.7 [3.3] weeks' gestation) until delivery. Infants were administered the DTP vaccine at 8, 12, and 16 weeks of age according to the Gambian Government protocol. Results for the primary outcome of the trial (infant thymic size) were described previously; here, we report on a secondary outcome, infant antibody response to vaccination. The effects of supplementation on mean DTP antibody titres measured in blood samples collected from infants at 12 weeks (n = 710) and 24 weeks (n = 662) were analysed with adjustment for confounders including maternal age, compliance to supplement, and infant sex and season. At 12 weeks, following a single dose of the vaccine, compared with FeFol (mean 95% confidence interval [CI]; 0.11 IU/mL, 0.09-0.12), antenatal supplementation with MMN or MMN + PE resulted in 42.4% (95% CI 20.1-64.6; p < 0.001) and 29.4% (6.4-52.5; p = 0.012) higher mean anti-diphtheria titres, respectively. Mean anti-tetanus titres were higher by 9.0% (5.5-12.5), 7.8% (4.3-11.4), and 7.3% (4.0-10.7) in MMN, PE, and PE + MMN groups (all, p < 0.001), respectively, than in the FeFol group (0.55 IU/mL, 0.52-0.58). Mean anti-pertussis titres were not significantly different in the FeFol, MMN, and PE + MNN groups but were all higher than in the PE group (all, p < 0.001). At 24 weeks, following all three doses, no significant differences in mean anti-diphtheria titres were detected across the supplement groups. Mean anti-tetanus titres were 3.4% (0.19-6.5; p = 0.038) higher in the PE + MMN group than in the FeFol group (3.47 IU/mL, 3.29-3.66). Mean anti-pertussis titres were higher by 9.4% (3.3-15.5; p = 0.004) and 15.4% (9.6-21.2; p < 0.001) in PE and PE + MMN groups, compared with the FeFol group (74.9 IU/mL, 67.8-82.8). Limitations of the study included the lack of maternal antibody status (breast milk or plasma) or prevaccination antibody measurements in the infants. According to our results from rural Gambia, maternal supplementation with MMN combined with PE during pregnancy enhanced antibody responses to the DTP vaccine in early infancy. Provision of nutritional supplements to pregnant women in food insecure settings may improve infant immune development and responses to EPI vaccines. ISRCTN49285450.

Sections du résumé

BACKGROUND
Exposure to a nutritionally deficient environment during fetal life and early infancy may adversely alter the ontogeny of the immune system and affect an infant's ability to mount an optimal immune response to vaccination. We examined the effects of maternal nutritional supplementation during pregnancy on infants' antibody responses to the diphtheria-tetanus-pertussis (DTP) vaccine included in the Expanded Programme on Immunisation (EPI).
METHODS AND FINDINGS
The Early Nutrition and Immune Development (ENID) trial was a randomised, partially blinded trial conducted between April 2010 and February 2015 in the rural West Kiang region of The Gambia, a resource-poor region affected by chronic undernutrition. Pregnant women (<20 weeks' gestation) with a singleton pregnancy (n = 875) were randomised to receive one of four supplements: iron-folic acid (FeFol; standard of care), multiple micronutrient (MMN), protein-energy (PE), or PE + MMN daily from enrolment (mean [SD] 13.7 [3.3] weeks' gestation) until delivery. Infants were administered the DTP vaccine at 8, 12, and 16 weeks of age according to the Gambian Government protocol. Results for the primary outcome of the trial (infant thymic size) were described previously; here, we report on a secondary outcome, infant antibody response to vaccination. The effects of supplementation on mean DTP antibody titres measured in blood samples collected from infants at 12 weeks (n = 710) and 24 weeks (n = 662) were analysed with adjustment for confounders including maternal age, compliance to supplement, and infant sex and season. At 12 weeks, following a single dose of the vaccine, compared with FeFol (mean 95% confidence interval [CI]; 0.11 IU/mL, 0.09-0.12), antenatal supplementation with MMN or MMN + PE resulted in 42.4% (95% CI 20.1-64.6; p < 0.001) and 29.4% (6.4-52.5; p = 0.012) higher mean anti-diphtheria titres, respectively. Mean anti-tetanus titres were higher by 9.0% (5.5-12.5), 7.8% (4.3-11.4), and 7.3% (4.0-10.7) in MMN, PE, and PE + MMN groups (all, p < 0.001), respectively, than in the FeFol group (0.55 IU/mL, 0.52-0.58). Mean anti-pertussis titres were not significantly different in the FeFol, MMN, and PE + MNN groups but were all higher than in the PE group (all, p < 0.001). At 24 weeks, following all three doses, no significant differences in mean anti-diphtheria titres were detected across the supplement groups. Mean anti-tetanus titres were 3.4% (0.19-6.5; p = 0.038) higher in the PE + MMN group than in the FeFol group (3.47 IU/mL, 3.29-3.66). Mean anti-pertussis titres were higher by 9.4% (3.3-15.5; p = 0.004) and 15.4% (9.6-21.2; p < 0.001) in PE and PE + MMN groups, compared with the FeFol group (74.9 IU/mL, 67.8-82.8). Limitations of the study included the lack of maternal antibody status (breast milk or plasma) or prevaccination antibody measurements in the infants.
CONCLUSION
According to our results from rural Gambia, maternal supplementation with MMN combined with PE during pregnancy enhanced antibody responses to the DTP vaccine in early infancy. Provision of nutritional supplements to pregnant women in food insecure settings may improve infant immune development and responses to EPI vaccines.
TRIAL REGISTRATION
ISRCTN49285450.

Identifiants

pubmed: 31386660
doi: 10.1371/journal.pmed.1002854
pii: PMEDICINE-D-19-00299
pmc: PMC6684039
doi:

Substances chimiques

Diphtheria-Tetanus-Pertussis Vaccine 0

Banques de données

ISRCTN
['ISRCTN49285450']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1002854

Subventions

Organisme : Medical Research Council
ID : G0501839
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC-A760-5QX00
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P012019/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U123292701
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00026/3
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

BMC Med. 2019 Feb 18;17(1):38
pubmed: 30773140
JAMA. 2012 May 16;307(19):2050-9
pubmed: 22665104
Semin Immunopathol. 2017 Nov;39(6):627-642
pubmed: 29124321
Malar J. 2018 Feb 07;17(1):74
pubmed: 29415730
Philos Trans R Soc Lond B Biol Sci. 2015 Jun 19;370(1671):
pubmed: 25964453
Lancet. 2008 Jan 19;371(9608):243-60
pubmed: 18207566
Lancet. 2013 Aug 3;382(9890):427-451
pubmed: 23746772
Proc Biol Sci. 2015 Dec 22;282(1821):20143085
pubmed: 26702035
Int J Epidemiol. 2017 Apr 1;46(2):e13
pubmed: 26559544
BJOG. 2013 Sep;120 Suppl 2:9-26, v
pubmed: 23678873
BMC Pregnancy Childbirth. 2012 Oct 11;12:107
pubmed: 23057665
J Immunol Methods. 2008 Jun 1;335(1-2):79-89
pubmed: 18407287
Trop Med Int Health. 2006 Oct;11(10):1529-41
pubmed: 17002727
Arch Dis Child. 1984 Jul;59(7):614-9
pubmed: 6465929
Curr Opin HIV AIDS. 2010 Sep;5(5):404-8
pubmed: 20978381
Hum Vaccin Immunother. 2018;14(10):2478-2484
pubmed: 29923793
Am J Clin Nutr. 2009 Dec;90(6):1593-600
pubmed: 19812173
Vaccine. 2015 Nov 25;33(47):6469-72
pubmed: 26256526
J Trop Pediatr. 2006 Oct;52(5):316-23
pubmed: 16621858
Philos Trans R Soc Lond B Biol Sci. 2015 Jun 19;370(1671):
pubmed: 25964459
Hum Vaccin. 2010 Jun;6(6):506-11
pubmed: 20519938
Clin Diagn Lab Immunol. 2005 Sep;12(9):1057-62
pubmed: 16148171
Br Med J (Clin Res Ed). 1982 Aug 28-Sep 4;285(6342):592-5
pubmed: 6819029
Lancet Glob Health. 2017 Nov;5(11):e1090-e1100
pubmed: 29025632
Paediatr Perinat Epidemiol. 2006 May;20(3):251-9
pubmed: 16629700
Sci Transl Med. 2011 Jul 6;3(90):90ps27
pubmed: 21734174
JAMA Pediatr. 2017 Jul 1;171(7):637-646
pubmed: 28505244
BMJ. 1997 Sep 27;315(7111):786-90
pubmed: 9345173
Future Virol. 2017 Sep;12(9):525-536
pubmed: 29225661
J Nutr. 2009 Nov;139(11):2154S-218S
pubmed: 19793845
Am J Clin Nutr. 2015 Feb;101(2):387-97
pubmed: 25646337
Adv Nutr. 2011 Sep;2(5):377-95
pubmed: 22332080
Eur J Nutr. 2016 Aug;55(5):1823-9
pubmed: 26208687
Eur J Clin Nutr. 2005 Sep;59(9):1081-9
pubmed: 16015266

Auteurs

Sandra G Okala (SG)

Kings' College London, Department of Women and Children's Health, St Thomas' Hospital, London, United Kingdom.

Momodou K Darboe (MK)

MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.

Fatou Sosseh (F)

MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.

Bakary Sonko (B)

MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.

Tisbeh Faye-Joof (T)

MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.

Andrew M Prentice (AM)

MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.

Sophie E Moore (SE)

Kings' College London, Department of Women and Children's Health, St Thomas' Hospital, London, United Kingdom.
MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH